logo
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--Jan 27, 2025--
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ('Atara' or 'the Company') (NASDAQ: ATRA) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Atara announced on January 16, 2025, that it had received 'a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the EBVALLO TM (tabelecleucel) Biologics License Application (BLA) as monotherapy treatment for adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen.' According to the Company, 'The CRL was solely related to observations as part of a standard pre-license inspection of a third-party manufacturing facility for EBVALLO.'
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Brian Schall, Esq.
310-301-3335
SOURCE: The Schall Law Firm
Copyright Business Wire 2025.
PUB: 01/27/2025 10:43 AM/DISC: 01/27/2025 10:43 AM

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

Yahoo

time18 minutes ago

  • Yahoo

Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval

Mesoblast experienced a 15% increase in its share price over the past week, largely driven by a significant orphan-drug approval by the U.S. FDA for Ryoncil. This approval, granting seven years of exclusivity for a vital treatment, likely bolstered investor confidence given the strengthened competitive positioning of Mesoblast. While broader market trends saw the S&P 500 and Nasdaq reach new highs amid positive investor sentiment on U.S.-China trade discussions, Mesoblast's specific gains were more tied to its unique developments, as they provided a substantial boost, counterbalancing broader market movements. You should learn about the 1 warning sign we've spotted with Mesoblast. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. Over the past three years, Mesoblast's total shareholder return, including share price changes and dividends, reached 181.00%. Despite recent gains driven by the U.S. FDA's orphan-drug approval for Ryoncil, the company's one-year performance outpaced the broader Australian Biotechs industry, which returned 12.3% less in the same timeframe. This highlights significant investor confidence and a positive reception to recent strategic advancements. While Mesoblast's share price has experienced impressive growth, it still trades at approximately 88% below consensus analyst price targets. The approval of Ryoncil positions the company competitively, potentially boosting future revenue, as evidenced by the expanded insurance coverage to 104 million U.S. lives. However, Mesoblast remains unprofitable, with A$47.93 million in net losses reported in its recent earnings. Analysts forecast substantial revenue growth at 56.7% annually, but profit forecasts show continued challenges for the next three years. The stock's recent appreciation reflects increased optimism, although the gap between the current share price and targeted fair value suggests room for further market adjustments. Our comprehensive valuation report raises the possibility that Mesoblast is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:MSB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst
SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst

Business Insider

time26 minutes ago

  • Business Insider

SailPoint, Inc. (SAIL) Receives a Rating Update from a Top Analyst

TD Cowen analyst Shaul Eyal maintained a Buy rating on SailPoint, Inc. (SAIL – Research Report) today. The company's shares closed today at $22.53. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Eyal is a top 25 analyst with an average return of 26.7% and a 69.56% success rate. Eyal covers the Technology sector, focusing on stocks such as Cloudflare, SailPoint, Inc., and Check Point. In addition to TD Cowen, SailPoint, Inc. also received a Buy from Barclays's Saket Kalia in a report issued on June 3. However, today, Mizuho Securities reiterated a Hold rating on SailPoint, Inc. (NASDAQ: SAIL). SAIL market cap is currently $10.94B and has a P/E ratio of -17.86. Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SAIL in relation to earlier this year.

NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion
NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion

Yahoo

time30 minutes ago

  • Yahoo

NVIDIA (NVDA) Gets Buy Rating as AI Data Center Demand Surges Past $50 Billion

NVIDIA Corporation (NASDAQ:NVDA) is one of the 10 AI Stocks on Wall Street's Radar. One of the most notable analyst calls on Tuesday, June 10, was for NVIDIA Corporation (NASDAQ:NVDA). Bank of America reiterated the stock as 'Buy,' stating that data center demand trends remain robust for Nvidia. 'Developing AI infrastructure leveraging local datasets and workforces is a rapidly growing global phenomenon and we expect it to contribute $50bn+ annually or 10%+ of long-term AI addressable market.' A powerful aerial view of the company's data center, exemplifying the digital services and informatics being offered. In other latest news, Nvidia Corporation and Hewlett-Packard Enterprise said on Tuesday that they are partnering with the Leibniz Supercomputing Centre to build a new supercomputer using Nvidia's next-generation chips. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store